Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Tetrandrine Tablets in Treating Interstitial Lung Disease Related to Connective Tissue Disease
NCT07319598 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Tetrandrine Tablets in Treating Interstitial Lung Disease Related to Connective Tissue Disease
- Lead sponsor
- Peking University Third Hospital
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- November 2, 2023
- Completion date
- January 1, 2027
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
connective tissue disease-associated interstitial lung disease, interstitial lung disease (ild)